Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)

A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment

Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses and long survivals have been described in patients having interrupted the treatment. In the melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of the study is to demonstrate that a treatment of 6 months followed by an observation (stop and go) is not less effective than a treatment given until progression or toxicity. This strategy would allow to decrease the accumulated toxicities, to improve the quality of life of the patients and to decrease the costs.

Study Overview

• Status: Active, not recruiting
• Conditions: Non-Small Cell Lung Cancer Metastatic
• Intervention / Treatment: Drug: Nivolumab; Drug: Ipilimumab

• Study Type: Interventional
• Enrollment (Actual): 265
• Phase: Phase 3

Contacts and Locations

Study Locations

• France
  • Amiens, France
    • Amiens - CHU
  • Angers, France, 49000
    • Angers - CHU
  • Annecy, France, 74374
    • Annecy - CH
  • Argenteuil, France, 95100
    • Argenteuil -CH
  • Avignon, France
    • Avignon - CH
  • Bordeaux, France
    • Bordeaux - Polyclinique Nord
  • Boulogne-Billancourt, France
    • Boulogne - Ambroise Paré
  • Caen, France, 14000
    • Caen - CHU Côte de Nacre
  • Cahors, France, 46000
    • Cahors - CH
  • Cergy Pontoise, France
    • CH de Pontoise
  • Chambery, France
    • CH Chambery
  • Chauny, France
    • CH de Chauny
  • Cholet, France
    • CH
  • Clamart, France, 92140
    • Clamart - Hôpital Percy
  • Clermont Ferrand, France, 63000
    • Clermont Ferrand - CHU
  • Colmar, France, 68000
    • Colmar - CH
  • Dijon, France, 21000
    • Dijon - CAC
  • Grenoble, France
    • CHRU Grenoble
  • La Roche Sur Yon, France, 85925
    • La Roche Sur Yon - CH
  • Le Mans, France, 72000
    • Centre Hospitalier - Pneumologie
  • Lille, France
    • CHRU de Lille
  • Limoges, France
    • CHU de Limoges
  • Lyon, France
    • CH Lyon Sud - Pneumologie
  • Marseille, France
    • Institut Paoli Calmette
  • Marseille, France
    • Marseille - Hôpital Européen
  • Mont de Marsan, France, 40000
    • Mont de Marsan - CH
  • Mulhouse, France, 68000
    • Mulhouse - CH
  • Nantes, France, 44805
    • Nantes - Centre René Gauducheau
  • Nice, France
    • Centre Antoine Lacassagne
  • Nîmes, France
    • Chu Nimes
  • Orléans, France, 45000
    • Orléans - CH
  • Paris, France
    • GH Paris Saint-Joseph
  • Paris, France, 75020
    • AP-HP Hopital Tenon - Pneumologie
  • Paris, France
    • AP-HP Hôpital Bichat
  • Paris, France
    • Hôpital Saint Louis APHP
  • Paris, France
    • Paris - Institut Curie
  • Rouen, France, 76000
    • Rouen - CHU
  • Saint Quentin, France, 02100
    • Saint Quentin - CH
  • Saint-Cloud, France
    • Centre René Huguenin
  • Saint-Mandé, France
    • HIA Begin
  • Saint-Priest-en-Jarez, France
    • ICL Lucien Neuwirth
  • Suresnes, France, 92151
    • Suresnes - Hopital Foch
  • Toulon, France, 83000
    • Toulon - CHI
  • Toulouse, France
    • CHU Toulouse
  • Tours, France
    • CHRU de Tours
  • Versailles, France, 78157
    • Versailles - CH
  • Villefranche, France
    • CH de Villefranche - Pneumologie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed Written Informed Consent:

   Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.

   Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.

2. Histologically-proven NSCLC (squamous or non-squamous)
3. Stage IV (M1, including M1a pleural involvement) disease (8th classification TNM, UICC 2015)
4. ECOG PS < 1
5. Weight loss< 10% in previous 3 months
6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease.
7. Age≥ 18 years, <75 years
8. Life expectancy > 3 months
9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria
10. Available tumor samples for centralized PD-L1 immunohistochemistry analysis
11. PD-L1 tumor content ≥ 1% and < 50% tumor cells as assessed locally by the investigator center

12. Adequate biological functions:

    Creatinine Clearance ≥ 50 mL/min (Cockcroft or MDRD or CKD-epi); neutrophiles ≥ 1500/mm3 ; platelets ≥100 000/mm3 ; Hemoglobin ≥ 9g/dL ; hepatic enzymes < 3x ULN, total bilirubin ≤ 1,5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic metastases (≤ 3,0 mg/dL)

13. Women of childbearing potential (WOCBP) and sexually active should use an efficacious contraception method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.

    For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 7 months following the last dose.

    Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly. At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective.

14. Patient inclusion validated by a multidisciplinary meeting.

Exclusion Criteria:

1. Small cell lung cancer or tumors with mixt histology including a SCLC component
2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18) or HER exon 20 insertion (either tissue or plasma cfDNA mutation).
3. Known ALK or ROS1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS sequencing
4. Previous or active cancer within the previous 5 years (except for treated carcinoma in situ of the cervix or basal cell skin cancer). Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (≤ T2a and Score de Gleason ≤ 6 and PSA (ng/ml) ≤ 10), provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy)
5. Superior vena cava (SVC) syndrome persisting after SVC stenting
6. Thoracic radiotherapy needed at initiation of tumor treatment, except bone palliative radiotherapy on a painful or compressive metastasis, respecting 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment
7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol infusions, with no evolution on brain MRI or CT-scan within the previous month are allowed.
8. History of previous primary immunodeficiency, organ transplantation needing an immunosuppressive treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3/4) by immune mechanism linked to another immunotherapy treatment.
9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.
10. History of active autoimmune disease including rheumatoid polyarthritis, Lupus, Wegener disease. Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) not needing any immunosuppressive systemic treatment, are allowed to be included.
11. Active inflammatory intestinal disease (diverticulosis, Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea
12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included.
13. HIV known infection
14. Living attenuated vaccine received within the 30 previous days
15. Previous treatment with anti-PD-1, anti-PD-L1 or Anti-CTLA4 antibody
16. Previous treatment with chemotherapy
17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction in the previous 6 months), history or stroke within the 6 previous months
18. Pre-existing lung interstitial disease as assessed by the diagnosis CT-scan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arm A : standard treatment; 6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended	Drug: Nivolumab; Nivolumab 3 mg/kg every 2 weeks; Drug: Ipilimumab; Ipilimumab 1 mg/kg every 6 weeks
Experimental: Arm B : experimental arm; 6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended	Drug: Nivolumab; Nivolumab 3 mg/kg every 2 weeks; Drug: Ipilimumab; Ipilimumab 1 mg/kg every 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS1)	Time between the date of randomization and the first date of documented progression, as determined by BICR (Blinded Independent Central Review), or death due to any cause, whichever occurs first.	24 months after randomization of the last subject

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS2)	Time between the start date of the second line and the second date of documented progression, as determined by BICR, or death due to any cause, whichever occurs first.	24 months after randomization of the last subject
Quality of life (QoL)	Time until definitive deterioration (TUDD) from the randomization time in the experimental arm B.	24 months after randomization of the last subject
Overall survival (OS)		6, 12 and 18 months after randomization
Biological correlative exploratory studies (PD-L1)	PD-L1-stained % of tumor cells will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months
Biological correlative exploratory studies (PD-L1 H score)	PD-L1 H-score will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months
Biological correlative exploratory studies (CD3/CD8)	CD3/CD8 tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months
Biological correlative exploratory studies (neutrophil)	neutrophil tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months
Biological correlative exploratory studies (cytokines)	plasma concentration of different cytokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months
Biological correlative exploratory studies (chemokines)	plasma concentration of different chemokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS	6 months

Collaborators and Investigators

• Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Publications and helpful links

Helpful Links

• IFCT website

Study record dates

Study Major Dates

• Study Start (Actual): May 2, 2018
• Primary Completion (Actual): November 8, 2023
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: February 16, 2018
• First Submitted That Met QC Criteria: March 12, 2018
• First Posted (Actual): March 19, 2018

Study Record Updates

• Last Update Posted (Actual): March 7, 2024
• Last Update Submitted That Met QC Criteria: March 6, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: NSCLC; IFCT; DICIPLE
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Nivolumab; Ipilimumab
• Other Study ID Numbers: IFCT-1701; 2017-002540-33 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No